Sanctuary Advisors LLC Increases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Sanctuary Advisors LLC raised its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 9.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,727 shares of the biopharmaceutical company’s stock after purchasing an additional 1,484 shares during the quarter. Sanctuary Advisors LLC’s holdings in Dynavax Technologies were worth $197,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its position in shares of Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after acquiring an additional 53,600 shares in the last quarter. Great Point Partners LLC grew its stake in Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Millennium Management LLC bought a new position in Dynavax Technologies in the second quarter valued at $17,615,000. Mizuho Markets Americas LLC lifted its position in Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after buying an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after purchasing an additional 82,449 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $13.00 on Monday. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 100.01 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The business’s fifty day moving average price is $12.45 and its 200-day moving average price is $11.54.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.